| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7642258 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7030149 | ABBVIE | Combination of brimonidine timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US9907801 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US9907802 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US8133890 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US8354409 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US8748425 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US7320976 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US9770453 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US9474751 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US7323463 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Jan, 2023
(1 year, 2 months ago) | |
Combigan is owned by Abbvie.
Combigan contains Brimonidine Tartrate; Timolol Maleate.
Combigan has a total of 11 drug patents out of which 11 drug patents have expired.
Expired drug patents of Combigan are:
- US7030149
- US9907801
- US9907802
- US8133890
- US8354409
- US8748425
- US7320976
- US9770453
- US9474751
- US7323463
- US7642258
Combigan was authorised for market use on 30 October, 2007.
Combigan is available in solution/drops;ophthalmic dosage forms.
Combigan can be used as reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of combigan in the affected eye twice daily, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy to brimonidine 0.2% tid, reduction of intraocular pressure in patients with elevated intraocular pressure or glaucoma, reduction of elevated intraocular pressure, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with a reduction in specified adverse events, compared to brimonidine 0.2% tid, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy, and a reduction in specified adverse events, compared to brimonidine 0.2% tid, reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop.
The generics of Combigan are possible to be released after 19 January, 2023.
Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient
Market Authorisation Date: 30 October, 2007
Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of ...
Dosage: SOLUTION/DROPS;OPHTHALMIC
COMBIGAN family patents
